Fluoroquinolones should not be the first-line antibiotics to treat community-acquired pneumonia in areas of tuberculosis endemicity [1]

Clinical Infectious Diseases

Volumn 45, Issue 1, 2007, Pages 133-

  Singh, Akashdeep ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; COMMUNITY ACQUIRED PNEUMONIA; DELAYED DIAGNOSIS; DRUG INDICATION; DRUG RESISTANT TUBERCULOSIS; DRUG TREATMENT FAILURE; ENDEMIC DISEASE; HEALTH CARE MANAGEMENT; HUMAN; INCIDENCE; LETTER; PRACTICE GUIDELINE; PRIORITY JOURNAL; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; FLUOROQUINOLONES; HUMANS; PNEUMONIA; PNEUMONIA, BACTERIAL; TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 34250870630     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/518708     Document Type: Letter

References (5)

1. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27-72.
2. Udwadia ZF, Doshi AV, Joshi JM, Rodrigues CS, Ladhani SS. Etiology of community acquired pneumonia in India. Eur Respir J 2003; 22: (Suppl 45)544s.
3. Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002; 34:1607-12.
4. Sullivan EA, Kreiswirth BN, Palumbo L, et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995; 345: 1148-50.
5. Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55:301-5.